AngioDynamics, Inc.
Clinical trials sponsored by AngioDynamics, Inc., explained in plain language.
A medical device company focused on minimally invasive vascular products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New device sucks out deadly heart infections without open surgery Results expected Nov 2026 (estimated)
- New device aims to make clot removal safer for lung patients Results expected Dec 2026 (estimated)
-
New NanoKnife treatment shows promise for prostate cancer
Disease control CompletedThis study tested a device called NanoKnife to treat prostate cancer in 121 men with intermediate-risk disease. The goal was to safely destroy cancer tissue while avoiding major side effects. Researchers checked if the treated area was cancer-free after 12 months and tracked any …
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Laser catheter shows promise for unclogging leg arteries
Disease control CompletedThis study looked at how well the AURYON atherectomy device works for people with peripheral artery disease (PAD), where leg arteries become blocked. The device uses a laser to vaporize plaque and restore blood flow. Researchers followed 102 patients to see if the procedure was s…
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC